Newsroom

GREENBROOK TMS ANNOUNCES EXPANSION INTO TAMPA-ST. PETERSBURG FLORIDA

January 9, 2018 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, is pleased to announce the expansion of its TMS Center network into the Tampa-St. Petersburg Metropolitan region. The Company will begin operating three TMS Centers in the Tampa-St. Petersburg, Florida region.   

Greenbrook expects to open additional TMS Centers in the Tampa-St. Petersburg Metropolitan area as part of its regional development strategy.

Read More  >


GREENBROOK TMS ANNOUNCES EXPANSION INTO CLEVELAND OHIO

December 28, 2018 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States, is pleased to announce the expansion of its TMS Center network into the Cleveland Metropolitan region. The Company will begin operating two TMS Centers in Cleveland, Ohio.

Greenbrook expects to open additional TMS Centers in the Cleveland Metropolitan area as part of its regional development strategy.

Read More  >


GREENBROOK TMS CONTINUES SUCCESSFUL EXECUTION OF GROWTH STRATEGY AND REPORTS THIRD QUARTER FINANCIAL RESULTS

November 12, 2018 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”) today announced its third quarter 2018 operational and financial results. For more information, please refer to Management’s Discussion and Analysis of Financial Condition and Results of operations (“MD&A”) and the unaudited condensed interim consolidated financial statements for the three- and nine-month periods ended September 30, 2018 and 2017. These documents will be available under the Company’s SEDAR profile at www.sedar.com. All values in this news release are in United States dollars unless otherwise stated. 

Bill Leonard, President and Chief Executive Officer of Greenbrook commented: 
“We are very pleased with our results this quarter. In addition to a strong performance from our existing centers we have continued to execute our growth strategy. In this quarter alone, we expanded our TMS Center network with 5 new centers. Subsequently, we opened an additional 3 regions bringing our total to 48 centers across 8 management regions.”

Read More  >


GREENBROOK TMS CENTERS BEGIN TO TREAT OBSESSIVE COMPULSIVE DISORDER WITH TMS THERAPY

November 8, 2018 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States for the treatment of Major Depressive Disorder (“MDD”), is pleased to announce that its TMS Centers will begin to offer treatment for Obsessive Compulsive Disorder (“OCD”). The treatment, which will be rolled out throughout the Company’s TMS Center network, delivers targeted magnetic pulses into the region of the brain implicated in OCD. As with all other TMS therapy provided at Greenbrook’s TMS Centers, this outpatient, office-based treatment is FDA-cleared, safe and non-invasive. Patients can resume daily activities immediately following a treatment session. 

OCD is a condition which causes intrusive and recurring obsessions and/or compulsions that interfere with a person’s daily activities and quality of life. Over 2 million adults in the United States are diagnosed with OCD each year. Conventional OCD treatments are only effective in about 50% of cases. 

Dr. Geoffrey Grammer, Chief Medical Officer of the Company stated: “The launch of this OCD treatment demonstrates our commitment to utilizing the latest developments in Transcranial Magnetic Stimulation to offer our patients the very best care possible. The H7 coil system developed by Brainsway provides us the new capability to treat areas of the brain involved in OCD and provide patients a truly novel approach to symptom relief.”

Read More  >


GREENBROOK TMS ANNOUNCES EXPANSION INTO HOUSTON TEXAS

October 31, 2018 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States for the treatment of Major Depressive Disorder (“MDD”), is pleased to announce the expansion of its TMS Center network into the Greater Houston region. As part of Greenbrook’s continued expansion into the State of Texas, the Company will begin operating a TMS Center in Sugar Land, Texas under the clinical leadership of Dr. Kimberly Cress, a current member of the Board of Directors of the Clinical TMS Society, and a leader in the field of TMS and neuromodulation.

Greenbrook expects to open additional TMS Centers in the Greater Houston area as part of its regional development strategy.

“I am thrilled for this opportunity to join Greenbrook TMS as they continue their expansion in Texas. As an experienced TMS provider since 2010, I look forward to working with Greenbrook, its physician partners and staff to continue to increase awareness of TMS and to provide more individuals with access to this potentially life changing therapy”, said Dr. Cress. Dr. Cress will serve as a Regional Medical Director of the Company.

Read More  >


GREENBROOK TMS ANNOUNCES DATES FOR ITS THIRD QUARTER 2018 RESULTS

October 29, 2018 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the“Company”) will release its third quarter 2018 operational and financial results after market hours on November 12, 2018.

Bill Leonard, President and Chief Executive Officer, and Erns Loubser, Chief Financial Officer, will host a conference call at 10:00 a.m. (Eastern Time) on November 13, 2018 to discuss the financial results for the quarter. 

Read More  >


GREENBROOK TMS ANNOUNCES EXPANSION INTO AUSTIN TEXAS

October 23, 2018 – Toronto, ON – Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States for the treatment of Major Depressive Disorder (“MDD”), is pleased to announce the expansion of its TMS Center network into the Austin Metropolitan region. The Company’s subsidiary, Greenbrook TMS Austin Central LLC (“Greenbrook TMS Austin”), will begin operating a TMS Center in Central Austin, Texas. Greenbrook TMS Austin marks the initial expansion of Greenbrook’s TMS Center network throughout the State of Texas.

Read More  >


GREENBROOK TMS ANNOUNCES EXPANSION INTO CONNECTICUT

October 16, 2018 – Toronto, ON – Greenbrook TMS Inc. (“Greenbrook” or the “Company”) (TSX:GTMS), a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States for the treatment of Major Depressive Disorder (“MDD”), is pleased to announce the expansion of its TMS Center network into the State of Connecticut. The Company’s subsidiary, Greenbrook TMS Connecticut LLC (“Greenbrook TMS Connecticut”), will begin operating two TMS Centers in Westport and Milford, Connecticut under the clinical leadership of Dr. Serena-Lynn Brown.

Greenbrook expects to partner with other physicians to open additional TMS Centers in Connecticut as part of its regional development strategy.

“We are very pleased to be partnering with Greenbrook as they begin their expansion in the Connecticut region. With this partnership we hope to promote increased awareness, affordability, and quality of care for TMS therapy patients in Connecticut”, said Dr. Brown. Dr. Brown will serve as Medical Director of Greenbrook TMS Connecticut.

Read More  >


GREENBROOK TMS ANNOUNCES LISTING ON THE TORONTO STOCK EXCHANGE

October 3, 2018 – Toronto, ON – Greenbrook TMS Inc., a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States for the treatment of Major Depressive Disorder (“MDD”), today announced that the Toronto Stock Exchange (“TSX”) has accepted the Company’s listing application to list its common shares on the TSX. The Company’s common shares will begin trading at the opening of markets today under the symbol “GTMS”.

Additional information in respect of Greenbrook’s business is available in its (final) long form prospectus dated September 27, 2018,, available under the Company’s SEDAR profile at www.sedar.com.

Read More  >


GREENBROOK TMS ANNOUNCES FILING OF FINAL PROSPECTUS

September 27, 2018 – Toronto, ON – Greenbrook TMS Inc., a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy in the United States for the treatment of Major Depressive Disorder (“MDD”), today announced that it has filed and obtained a receipt for its final prospectus from the applicable Canadian securities regulatory authorities.

The Prospectus qualifies the distribution of 10,000,000 common shares of Greenbrook issuable upon exercise or deemed exercise of 10,000,000 special warrants (the “Special Warrants”). The Special Warrants were issued to purchasers in March and June 2018 at a price of US$2.00 per Special Warrant, pursuant to prospectus exemptions under applicable securities legislation, for aggregate gross proceeds of US$20 million.

Read More  >